Hepatitis and HIV

Hepatitis and HIV features

• 

  Full speed ahead to curing hepatitis C

  New drugs that directly target the hepatitis C virus usher in a new era of treatment, Liz Highleyman reports. ...

  From:  HIV treatment update

• 

  We’re getting there: towards a comprehensive hepatitis C cure

  Research on new cures for hepatitis C has made rapid progress, Gus Cairns reports....

  From:  HIV treatment update

• 

  Staying safe inside: HIV and hepatitis C health care in prison

  Policies on safer sex and needle exchange in UK prisons seem to have stalled. With a high and increasing prevalence of hepatitis C in our jails, and...

  From:  HIV treatment update

• 

  Staying free of hepatitis C

  It's still not clear exactly how HIV-positive gay men are contracting hepatitis C through sex. Until we know with certainty, Derek Thaczuk asks, how can we avoid co-infection?...

  From:  HIV treatment update

• 

  Combinations and conundrums: the challenges of hepatitis C treatment

  A multiplicity of new drugs for hepatitis C are being researched. As Gus Cairns discovers, though, they face an elusive enemy, a shape-shifter of a virus that won’t...

  From:  HIV treatment update

• 

  The new epidemic: HIV and hepatitis C infection in gay men

  “I’m surprised there isn’t a greater sense of urgency about this in the community.” Those were the words of Dr Kevin Fenton of the US Centers for...

  From:  HIV treatment update

• 

  Double trouble – how hepatitis C is on the increase in HIV-positive gay men

  Studies at CROI showed how hepatitis C is gaining ground, says Gus Cairns. ...

  From:  HIV treatment update

• 

  Management of HIV and hepatitis B or C co-infection in resource-limited settings

  Review of management of HIV and hepatitis co-infection with particular focus on antiretroviral therapy and liver disease in resource-limited settings....

  From:  HIV & AIDS treatment in practice

• 

  Viral hepatitis in low and middle-income settings

  Management of HIV and hepatitis B or C co-infection in resource-limited settings....

  From:  HIV & AIDS treatment in practice

• 

  HIV and hepatitis in non-injecting drug users

  Management of HIV and hepatitis in non-injecting drug users in resource-limited settings....

  From:  HIV & AIDS treatment in practice

Hepatitis and HIV in your own words

• 

  Living with HIV and hep C co-infection and haemophilia

  For most people, coping with HIV is enough of a problem in itself, but when you throw in a lifetime disorder such as haemophilia, and...

  From:In your own words

Hepatitis and HIV news from aidsmap

• Sofosbuvir plus ribavirin works well for hard-to-treat inner-city hepatitis C patients

  A simple 24-week oral regimen consisting of sofosbuvir plus full-dose ribavirin cured nearly 70% of previously untreated people with genotype 1 hepatitis C, many of whom had factors predictive of poor response, researchers reported last week at the 20th Conference on Retroviruses and Opportunistic Infections ...

  20 March 2013 | Liz Highleyman

• AbbVie interferon-free combinations cure most newly treated hepatitis C patients

  All-oral regimens consisting of the HCV protease inhibitor ABT-450, a non-nucleoside polymerase inhibitor and ribavirin led to sustained response for more than 90% of previously untreated hepatitis  C patients – including those with unfavourable IL28B gene patterns – but ...

  20 March 2013 | Liz Highleyman

• Even moderate alcohol consumption increases risk of death for people with chronic hepatitis C

  Moderate alcohol consumption - as little as one or two drinks per day -  is associated with an increased risk of mortality for people with chronic hepatitis C virus (HCV) infection, according to research conducted in the United ...

  18 March 2013 | Michael Carter

• Adding telaprevir improves acute hepatitis C treatment for HIV-positive men

  Adding telaprevir (Incivo or Incivek) to pegylated interferon and ribavirin shortens the duration of treatment and increases the likelihood of a cure for HIV-positive men with acute sexually transmitted hepatitis C virus (HCV), according to study findings presented last ...

  12 March 2013 | Liz Highleyman

• Simeprevir & sofosbuvir demonstrates good early cure rate with or without ribavirin

  An all-oral combination of simeprevir plus sofosbuvir, with or without ribavirin, led to an early cure for most hard-to-treat prior null responders with genotype 1 hepatitis C studied in the phase 2a COSMOS trial, according to a presentation last ...

  12 March 2013 | Liz Highleyman

• Faldaprevir ups interferon response in HIV/HCV co-infection

  Adding the hepatitis C virus (HCV) protease inhibitor faldaprevir (formerly BI 201335) to pegylated interferon and ribavirin led to a higher early response rate and the potential for shorter treatment for HIV/HCV co-infected people, according to a presentation last ...

  11 March 2013 | Liz Highleyman

• Simeprevir pushes HCV cure rate above 75% for HIV/HCV co-infection

  Adding the new hepatitis C virus (HCV) protease inhibitor simeprevir (formerly TMC435) to pegylated interferon and ribavirin cures about three-quarters of HIV/HCV co-infected people, most of them with a shortened course of therapy, researchers reported last week at the ...

  11 March 2013 | Liz Highleyman

• Dually active antiretroviral therapy protects against hepatitis B infection

  Use of antiretroviral therapy that includes drugs active against both hepatitis B virus (HBV) and HIV reduces the risk that people living with HIV will become infected with HBV – in effect acting as HBV pre-exposure prophylaxis (PrEP) ...

  07 March 2013 | Liz Highleyman

• French studies report real-world data on use of telaprevir and boceprevir in people with HIV and hepatitis C co-infection

  Adding boceprevir or telaprevir to interferon-based therapy showed promising indications of efficacy and acceptable safety for difficult-to-treat HIV/HCV co-infected prior non-responders in a pair of French studies presented yesterday at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.The advent of ...

  05 March 2013 | Liz Highleyman

• Sofosbuvir/ledipasvir/ribavirin cures 100% of genotype 1 hepatitis C patients

  An interferon-free regimen containing sofosbuvir (formerly GS-7997), ledipasvir (formerly GS-5885) and ribavirin produced a 12-week post-treatment sustained virological response (SVR12) rate of 100% for both treatment-naive hepatitis C patients and prior interferon non-responders, according to data presented yesterday at the ...

  05 March 2013 | Liz Highleyman

More news

Hepatitis and HIV news selected from other sources

• The New Deal: Gay Men, Sex, and Hep C

  A new website has been launched, in order to provide gay men with information about sexual transmission of hepatitis C and how to prevent it; testing for and treatment of hepatitis C; and information about HIV and hepatitis C co-infection.

  8 hours ago | AFAO

• High maternal viral load key to vertical transmission of hepatitis B

  High maternal viral load is the most important factor causing maternally transmitted hepatitis B virus (HBV) infection and is significantly correlated with e antigen (HBeAg) positivity, according to a prospective study from Taiwan.

  19 March 2013 | Medscape (requires registration)

• Expanding High Risk Population Drives European Hepatitis B and C Diagnostics Market

  New analysis from Frost & Sullivan, Analysis of the European Hepatitis B and C Diagnostics Market, estimates revenues of the hepatitis B diagnostics to grow from $165.9 million in 2012 to $260.2 million in 2019 and hepatitis C diagnostics market to grow from $3,140.8 million in 2012 to $4,940.9 million in 2019, respectively.

  13 March 2013 | PR Newswire (press release)

• England: lack of planning for hepatitis C services risks future chaos and huge healthcare costs

  New report finds that local authorities and NHS organisations need to prioritise hepatitis C now or risk missing a rare opportunity.

  11 March 2013 | Hepatitis C Trust press release

• Four in Five People With HIV and Hep C on Faldaprevir Achieve Early Treatment Success

  Interim results from a trial of the hep C drug faldaprevir, given to people coinfected with hep C and HIV, have shown an 80 percent early success rate.

  07 March 2013 | AIDSMeds

• Patient Dilemma: Treat Hepatitis C Now or Hold Out?

  Being diagnosed with a potentially fatal disease usually triggers immediate treatment. But a growing number of people infected with hepatitis C are putting off therapy, choosing instead to roll the dice and wait for a new generation of drugs to become available.

  05 March 2013 | Wall Street Journal

• HIV Accelerates Liver Fibrosis by Nearly a Decade Among People With Hep C

  Fibrosis in those coinfected with hepatitis C and HIV is comparable in severity to that found in people mono- infected with hep C who are nearly a decade older.

  01 March 2013 | Aidmeds

• UNITAID can address HCV/HIV co-infection

  In the first days of March, the governing body of UNITAID, the organisation financed mainly through a levy on air tickets, will decide on a new 4-year strategy. We believe UNITAID's new strategy should also include tackling a prevalent and serious, but curable, HIV co-morbidity: hepatitis C virus (HCV) infection.

  23 February 2013 | The Lancet

• Managing tuberculosis in people who use and inject illicit drugs

  The prevention, diagnosis and treatment of tuberculosis among people who use illicit drugs have been neglected and require immediate attention. Open dialogue on policy in this area should be encouraged, and a coordinated programme response from stakeholders working in prisons and in harm reduction, HIV infection, hepatitis and tuberculosis services should be sought.

  04 February 2013 | Bulletin of the World Health Organization

• Judge: Agency Could Have Stopped Exeter Hepatitis C Outbreak

  A judge said a medical staffing agency could have stopped a hepatitis C outbreak that infected 32 Exeter Hospital patients.

  30 January 2013 | Patch.com

More news